# | Website | Score in June 2020 | 1m changes |
---|
1 | Building the Chronology of Early Chinese History | 42 | 0 |
2 | Expansion and Contraction Patterns of Large Polities: Context for Russia | 42 | 0 |
3 | An Apocalypse Think Tank | 21 | 0 |
4 | Genomic Divergences between Humans and Other Hominoids and the Effective Population Size of the Common Ancestor of Humans and Chimpanzees | 21 | 0 |
5 | What makes a modern human | 21 | 0 |
6 | Biomes and human distribution during the last ice age | 21 | 0 |
7 | The Kingdom of Kush: An African Centre on the Periphery of the Bronze Age World System | 21 | 0 |
8 | 10.1093/qjmed/hcl076 | 21 | 0 |
9 | Art in Ancient Ife, Birthplace of the Yoruba | 21 | 0 |
10 | XXIV. Note on the theory of the greenhouse | 21 | 0 |
11 | 10.1038/scientificamerican0116-58 | 21 | 0 |
12 | Rapid diagnostic tests for diagnosing uncomplicated P. falciparum malaria in endemic countries | 16 | -9 |
13 | Response to Malaria Epidemics in Africa | 16 | -9 |
14 | Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria | 16 | -9 |
15 | Laboratory diagnosis of malaria in nonhuman primates | 16 | -9 |
16 | Understanding the population genetics of Plasmodium vivax is essential for malaria control and elimination | 16 | -9 |
17 | Spread of Artemisinin Resistance in Plasmodium falciparum Malaria | 16 | -9 |
18 | Anopheles gambiaeGenome: Completing the Malaria Triad | 16 | -9 |
19 | Malaria zoonoses | 16 | -9 |
20 | Evidence and Implications of Mortality Associated with Acute Plasmodium vivax Malaria | 16 | -9 |
21 | Intermittent preventive treatment of malaria in pregnant women and infants: making best use of the available evidence | 16 | -9 |
22 | CLINICAL ASPECTS OF UNCOMPLICATED AND SEVERE MALARIA | 16 | -9 |
23 | Redefining cerebral malaria by including malaria retinopathy | 16 | -9 |
24 | The therapeutic potential of metal-based antimalarial agents: Implications for the mechanism of action | 16 | -9 |
25 | Malaria Primer for Clinicians in the United States | 16 | -9 |
26 | Substandard medicines in resource-poor settings: a problem that can no longer be ignored | 16 | -9 |
27 | Plasmodium knowlesi:Finally Being Recognized | 16 | -9 |
28 | Plasmodium knowlesi: A Malaria Parasite of Monkeys and Humans | 16 | -9 |
29 | The cellular and molecular basis for malaria parasite invasion of the human red blood cell | 16 | -9 |
30 | History of Human Parasitology | 16 | -9 |
31 | Advances and challenges in malaria vaccine development | 16 | -9 |
32 | Malaria in the Greater Mekong Subregion: Heterogeneity and complexity | 16 | -9 |
33 | Artemisinin resistance: current status and scenarios for containment | 16 | -9 |
34 | Thiamin (Vitamin B1) Biosynthesis and Regulation: A Rich Source of Antimicrobial Drug Targets? | 16 | -9 |
35 | Electronic mosquito repellents for preventing mosquito bites and malaria infection | 16 | -9 |
36 | Malaria Management: Past, Present, and Future | 16 | -9 |
37 | Artemisinin-Resistant Malaria: Research Challenges, Opportunities, and Public Health Implications | 16 | -9 |
38 | Shrinking the malaria map: progress and prospects | 16 | -9 |
39 | The ’hidden’ burden of malaria: cognitive impairment following infection | 16 | -9 |
40 | Chemoprophylaxis in malaria: drugs, evidence of efficacy and costs | 16 | -9 |
41 | Malaria Prevention in Short-Term Travelers | 16 | -9 |
42 | A new world malaria map: Plasmodium falciparum endemicity in 2010 | 16 | -9 |
43 | Vaccines for preventing malaria (SPf66) | 16 | -9 |
44 | Malaria in 2002 | 16 | -9 |
45 | Spurious and counterfeit drugs: a growing industry in the developing world | 16 | -9 |
46 | Vaccines for preventing malaria (blood-stage) | 16 | -9 |
47 | Malaria | 16 | -9 |
48 | Assembling a global database of malaria parasite prevalence for the Malaria Atlas Project | 16 | -9 |
49 | The Changing Disease-Scape in the Third Epidemiological Transition | 16 | -9 |
50 | The impact of maternal malaria on newborns | 16 | -9 |
51 | Estimating the Global Clinical Burden of Plasmodium falciparum Malaria in 2007 | 16 | -9 |
52 | Population genetics of malaria resistance in humans | 16 | -9 |
53 | Vaccines against malaria | 16 | -9 |
54 | Technologies for global health | 16 | -9 |
55 | Reflections on the ’discovery’ of the antimalarial qinghao | 16 | -9 |
56 | Cerebral Malaria: Mechanisms of Brain Injury and Strategies for Improved Neurocognitive Outcome | 16 | -9 |
57 | Transgenic anopheline mosquitoes impaired in transmission of a malaria parasite | 16 | -9 |
58 | Drugs for preventing malaria in travellers | 16 | -9 |
59 | Malaria, Plasmodium falciparum and its apicoplast | 16 | -9 |
60 | Systematic review and meta-analysis: rapid diagnostic tests versus placental histology, microscopy and PCR for malaria in pregnant women | 16 | -9 |
61 | The Quest for Quinine: Those Who Won the Battles and Those Who Won the War | 16 | -9 |
62 | Dihydroartemisinin/Piperaquine | 16 | -9 |
63 | Eradication of Anopheles gambiae from Brazil: lessons for malaria control in Africa? | 16 | -9 |
64 | Ongoing challenges in the management of malaria | 16 | -9 |
65 | Malaria Attributable to the HIV-1 Epidemic, Sub-Saharan Africa | 16 | -9 |
66 | How Malaria Has Affected the Human Genome and What Human Genetics Can Teach Us about Malaria | 16 | -9 |
67 | Discoverers of quinine | 16 | -9 |
68 | Malaria in adolescence: burden of disease, consequences, and opportunities for intervention | 16 | -9 |
69 | Global malaria mortality between 1980 and 2010: a systematic analysis | 16 | -9 |
70 | Ecology and conservation biology of avian malaria | 16 | -9 |
71 | Insecticide-treated bed nets and curtains for preventing malaria | 16 | -9 |
72 | Counterfeit and substandard antimalarial drugs in Cambodia | 16 | -9 |
73 | The use of remotely sensed environmental data in the study of malaria | 16 | -9 |
74 | A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy | 16 | -9 |
75 | Molecular interactions in the placenta during malaria infection | 16 | -9 |
76 | Intermittent preventive treatment for malaria in children living in areas with seasonal transmission | 16 | -9 |
77 | Antipyretic measures for treating fever in malaria | 16 | -9 |
78 | Estimating the Number of Insecticide-Treated Nets Required by African Households to Reach Continent-wide Malaria Coverage Targets | 16 | -9 |
79 | Transgenic RodentPlasmodium bergheiParasites as Tools for Assessment of Functional Immunogenicity and Optimization of Human Malaria Vaccines | 16 | -9 |
80 | Plasmodium malariae and Plasmodium ovale – the ‘bashful’ malaria parasites | 16 | -9 |
81 | Vitamin B metabolism in Plasmodium falciparum as a source of drug targets | 16 | -9 |
82 | Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa | 16 | -9 |
83 | Counterfeit anti-infective drugs | 16 | -9 |
84 | A Collaborative Epidemiological Investigation into the Criminal Fake Artesunate Trade in South East Asia | 16 | -9 |
85 | Insecticide-treated net coverage in Africa: mapping progress in 2000–07 | 16 | -9 |
86 | Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum | 16 | -9 |
87 | Management of Severe Malaria: Results from Recent Trials | 16 | -9 |
88 | Transfusion‐Transmitted Malaria in Countries Where Malaria Is Endemic: A Review of the Literature from Sub‐Saharan Africa | 16 | -9 |
89 | WHO combats counterfeit malaria drugs in Asia | 16 | -9 |
90 | MOSQUITO BEHAVIOR AND VECTOR CONTROL | 16 | -9 |
91 | Working without a blindfold: the critical role of diagnostics in malaria control | 16 | -9 |
92 | Indoor residual spraying for preventing malaria | 16 | -9 |
93 | A Fresh Look at the Origin of Plasmodium falciparum, the Most Malignant Malaria Agent | 16 | -9 |
94 | Malaria vector control: from past to future | 16 | -9 |
95 | Cerebral malaria | 16 | -9 |
96 | SOCIAL IMPLICATIONS OF MALARIA AND THEIR RELATIONSHIPS WITH POVERTY | 16 | -9 |
97 | What is the evidence for the existence of Plasmodium ovale hypnozoites? | 16 | -9 |
98 | Malaria in pregnancy in the Asia-Pacific region | 16 | -9 |
99 | Immune mechanisms in malaria: new insights in vaccine development | 16 | -9 |
100 | Ferrocene-based antimalarials | 16 | -9 |
101 | Costs and financial feasibility of malaria elimination | 16 | -9 |
102 | The economic and social burden of malaria | 16 | -9 |
103 | Malaria and Rome | 16 | -9 |
104 | Critical Care Aspects of Malaria | 16 | -9 |
105 | Artesunate versus quinine for treating severe malaria | 16 | -9 |
106 | Challenges of drug-resistant malaria | 16 | -9 |
107 | Respiratory Manifestations of Malaria | 16 | -9 |
108 | The Plasmodium falciparum-infected red blood cell | 16 | -9 |
109 | Clinical review: Severe malaria | 16 | -9 |
110 | Systems immunology of human malaria | 16 | -9 |
111 | Drug Resistance in Plasmodium: Natural Products in the Fight Against Malaria | 16 | -9 |
112 | Mosquito larval source management for controlling malaria | 16 | -9 |
113 | Global Status of DDT and Its Alternatives for Use in Vector Control to Prevent Disease | 16 | -9 |
114 | Reflections on early malaria vaccine studies, the first successful human malaria vaccination, and beyond | 16 | -9 |
115 | Malaria Parasite Pre-Erythrocytic Stage Infection: Gliding and Hiding | 16 | -9 |
116 | The Forgotten Malaria | 16 | -9 |
117 | Genetic variation and susceptibility to infection: the red cell and malaria | 16 | -9 |
118 | Qinghaosu (Artemisinin): The Price of Success | 16 | -9 |
119 | Determinants of relapse periodicity in Plasmodium vivax malaria | 16 | -9 |
120 | Malaria Eradication in the United States | 16 | -9 |
121 | Malaria Rapid Diagnostic Tests | 16 | -9 |
122 | Declining Artesunate-Mefloquine Efficacy against Falciparum Malaria on the Cambodia–Thailand Border | 16 | -9 |
123 | Is malaria a disease of poverty? A review of the literature | 16 | -9 |